Physician profile
Karl E Waite
NPI 1598902579
$11,156.34
in general payments reported to CMS, 2019-2025
15 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $743 · 2021: $1,461 · 2022: $2,372 · 2023: $1,261 · 2024: $2,416 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850 · Honoraria: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.74 |
| Honoraria | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $3,467.94 | 2019-2022 | |
| Alimera Sciences, INC. | $2,427.53 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $1,292.73 | 2019-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $1,001.98 | 2023-2025 | Izervay |
| Genentech USA, INC. | $680.17 | 2021-2025 | Vabysmo, Susvimo |
| Abbvie INC. | $587.32 | 2022-2025 | Ozurdex |
| Alcon Vision LLC | $392.03 | 2019-2023 | Ngenuity, Constellation |
| Apellis Pharmaceuticals, INC. | $298.61 | 2022-2025 | Syfovre |
| Novartis Pharmaceuticals Corporation | $230.66 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $205.27 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $174.11 | 2019-2021 | |
| Harrow Eye, LLC | $172.73 | 2025 | Triesence, Iheezo |
| Ani Pharmaceuticals, INC. | $147.12 | 2024-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Bausch & Lomb Americas INC. | $40.48 | 2023-2024 | Xipere |
| Allergan, INC. | $37.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$76,113.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Waite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.